Fragile X Syndrome (FXS) is a genetic disease due to a CGG trinucleotide expansion, named full mutation (greater than 200 CGG repeats), in the fragile X mental retardation 1 gene locus Xq27.3; which leads to an hyper-methylated region in the gene promoter therefore silencing it and lowering the expression levels of the fragile X mental retardation 1, a protein involved in synaptic plasticity and maturation.
Fragile X Syndrome Epidemiology Insights
How will Disease transform Fragile X Syndrome Market?
According to DelveInsight, Fragile X Syndrome market size in 7MM in 2017 was USD 33.8 Million
The FXS market outlook of the report helps to build a detailed comprehension of the historical, current and forecasted FXS market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand of better technology.
This segment gives a thorough detail FXS market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.
To know more about Fragile X Syndrome Market, click here @ https://www.delveinsight.com/report-store/fragile-x-syndrome-fxs-market
Fragile X Syndrome Market Drivers
Fragile X Syndrome Market Barriers
For more information on Fragile X Syndrome Market trends, click here to get sample pages:- https://www.delveinsight.com/sample-request/fragile-x-syndrome-fxs-market
Media ContactCompany Name: DelveInsightContact Person: Priya MauryaEmail: Send EmailPhone: +919650213330City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/